*Minimum purchase of 4 singles apply. Please advise under 'Customer Instructions' if a specific minimum expiry date is required. Please remember to include the vaccine surcharge from freight and insurance section.
Parvac
Manufacturer: Pfizer Animal Health
Composition Inactivated vaccine prepared from canine parvovirus grown aseptically in a continuous cell line. An aluminium salt enhances the response to vaccination and increases the duration of immunity. Each batch conforms to accepted standards for safety, potency, purity and freedom from abnormal toxicity. Actions It has been shown that seronegative dogs and pups immunised with a single dose of Parvac develop antibody to canine parvovirus. Levels of antibody, considered to be protective, develop in most dogs about ten days after administration of the vaccine. Indications Immunisation of dogs against canine parvovirus infection where an inactivated vaccine is preferred. Do not use in dogs that are incubating an infectious disease; seriously debilitated by another infectious disease, parasitic infestation or malnutrition; or under treatment with immunosuppressive drugs. As it is an inactivated vaccine, untoward systemic effects are very rare and the vaccine may be used in pregnant bitches. The adjuvant will cause a temporary local reaction at the injection site, though this is seldom visible. Careful palpation may reveal a small fibrous nodule in some dogs about one week after vaccination. This nodule will regress, becoming impalpable within two to six weeks. In a very few small, smooth coated dogs, such a nodule may be visible for a limited period. Dosage and Administration Give a 1 mL dose by subcutaneous injection in dogs of all ages; gently massage injection site to help disperse the vaccine. Vaccination programs. Due to the ubiquity and persistence of virulent canine parvovirus in the environment and interference of maternal antibody with response to vaccination, protection of puppies up to 16 weeks of age can be difficult to achieve. This is particularly evident in kennels. Puppies born to seropositive bitches will likely acquire maternal antibody against parvovirus from colostrum, which should protect the puppy against virulent field virus during the first few weeks to months of life. Surveys indicate that many adult dogs are seropositive and that the prevalence of the cardiac syndrome in young pups due to parvovirus infection is declining. Nevertheless, vaccination of bitches prior to mating or whelping should be considered as a means of preventing infection of pups in utero or perinatally. However, maternal antibody to canine parvovirus sufficient to interfere with vaccination may persist in a proportion of puppies up to 16 weeks of age or more. Most adult dogs, seronegative pups and puppies over 18 weeks of age should be protected by a single dose of Parvac for a period of up to 12 months, after which time revaccination may be necessary. Administration of two doses, four weeks apart, to seronegative dogs produces a more durable immunity. Accepting that low levels of maternal antibody can interfere with the response to vaccination, and that some puppies of 16 to 18 weeks of age or more may retain sufficient maternal antibody to interfere with the response to vaccination with canine parvovirus vaccines, it is recommended that puppies be vaccinated on several occasions (e.g. at 6 to 8, 12 to 14, and 16 to 18 weeks of age) to reduce the interval between loss of maternal immunity and vaccination, and to ensure a satisfactory response. Also, as far as possible, direct or indirect contact of puppies with other dogs must be prevented. This program may be further modified for high risk animals and/or high risk situations. At risk puppies may be vaccinated every two to three weeks from 6 weeks through to 20 weeks of age. The epidemiology of this disease, the persistence of maternal antibody and the dog's history must all be considered when deciding on a vaccination program for a particular animal. Annual booster vaccinations are recommended to maintain adequate immunity.
